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Abstract
Introduction: Recently, we demonstrated that digestive tract cancer (DTC) is associated with reduced fibrin clot permeability 
and impaired fibrinolysis. 
Aim: We investigated determinants of fibrinolysis in DTC patients.
Material and methods: In 44 consecutive patients with DTC and 47 controls matched for age, sex, and cardiovascular risk, 
we evaluated fibrinolysis proteins, platelet activation markers, thrombin formation, together with plasma clot lysis time assays 
in the absence (CLT) and presence of carboxypeptidase potato inhibitor (CLT CPI) that blocks thrombin activatable fibrinolysis 
inhibitor (TAFI).
Results: In the DTC group CLT (by 22.3%) and CLT CPI (by 27.4%) were longer compared with controls. The DTC patients 
had higher plasma fibrinolysis inhibitors, plasminogen activator inhibitor 1 (PAI-1) (by 18.2%), TAFI activity (by 17.3%), and 
antigen (by 11.2%). The patients had markedly increased platelet markers – soluble CD40 ligand (by 338%) and P-selectin (by 
97%), together with von Willebrand factor (vWF) antigen (by 61%). Thrombin-antithrombin complexes (TAT) (by 48.7%) and 
soluble thrombomodulin (sTM) (by 17.2%) were also increased in the DTC group (all p < 0.05). Patients with high-grade tumours 
(n = 26) compared with remainders (n = 18) had longer CLT, higher tissue-type plasminogen activator antigen, both TAFI antigen 
and activity levels, vWF, and sTM. Multiple regression analysis after adjustment for potential confounders showed that inde-
pendent predictors of CLT in DTC patients were TAT, TAFI activity, and vWF. The only independent predictor of CLT CPI was TAT.
Conclusions: Hypofibrinolysis in DTC patients is largely driven by enhanced thrombin generation, TAFI, and endothelial injury.
Introduction
Thrombosis has a significant impact on the mor-
bidity and mortality in cancer patients [1]. The risk of 
a thrombotic event in patients with malignancy de-
pends on several factors, including the type of cancer, 
its clinical stage and grade, concomitant disease, and 
treatment. Elevated plasma D-dimer levels, which re-
flect a global activation of blood coagulation and fi-
brinolysis, are commonly observed in cancer patients 
and may predict poor prognosis [2, 3]. Global fibrino-
lytic capacity, detected with the amount of D-dimer 
produced by tissue-type plasminogen activator (tPA) 
from standard fibrin pellets, has also been shown to 
be increased in both metastatic and non-metastatic 
disease of patients with colorectal cancer, reflecting 
a progression to overt disseminated intravascular co-
agulation [4]. On the other hand, several reports have 
demonstrated increased circulating levels of fibrinoly-
sis inhibitors, including plasminogen activator inhibitor 
(PAI-1) [5] and thrombin activatable fibrinolysis inhibitor 
(TAFI), in cancer patients, including those with lung and 
gastric cancer [6–8], which suggests impaired fibrino-
lysis in this disease. The PAI-1 is a major physiological 
inhibitor of tPA, while TAFI is a proenzyme, which is con-
verted to its active form by thrombin in complex with 
thrombomodulin, and activated TAFI cleaves C-terminal 
lysine and arginine residues from partially degraded 
fibrin, thereby preventing tPA and plasminogen binding, 
which is necessary for efficient plasminogen activation 
[9]. α
2-Antiplasmin (α2AP) rapidly inhibits plasmin in 
solution, but not when bound to fibrin. Both TAFI and 
α
2AP are important in the inhibition and downregula-
tion of plasmin [9].
Higher antigen levels of urokinase-type plasmin-
ogen activator (u-PA), uPA receptor (uPAR), PAI-1, and 
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plasminogen activator inhibitor-2 (PAI-2) were found in 
colorectal cancer (CRC) tissue compared with normal 
tissue [10]. However, this mechanism appears to be 
of negligible importance for systemic fibrinolysis mea-
sured in plasma of venous blood.
Little is known about the links between circulating 
concentrations of fibrinolysis inhibitors and the stage 
of cancer. Langenskiold et al. reported a correlation 
between plasma PAI-1 and metastatic disease in CRC 
patients [11]. Fidan et al. found a positive association 
between plasma TAFI levels and lymph node invasion in 
gastric cancer patients [8]. It might be speculated that 
impaired fibrinolysis is more common among patients 
with advanced cancer.
Recently we have demonstrated that digestive tract 
cancer (DTC) patients present unfavourably altered 
clot properties, including faster clot formation, reduced 
clot permeability, and impaired susceptibility to lysis, 
which were evaluated in plasma of venous blood [12]. 
Patients with DTC had, among others, longer clot lysis 
time (+17%) compared with controls, which were in part 
related to increased thrombin-antithrombin (TAT) com-
plexes, a measure of thrombin generation, and plasma 
PAI-1 levels [12]. However, it is unclear whether other 
fibrinolysis inhibitors could contribute to hypofibrino-
lysis observed in cancer patients. The role of several 
proteins released from activated platelets and/or endo-
thelial cells in impaired fibrinolysis measured in plasma 
of venous blood also remains to be elucidated. 
Aim
Therefore, we decided to investigate which factors 




The DTC patients (n = 44) we investigated were pre-
viously described in detail [12]. In short, we enrolled 
consecutive patients with histologically confirmed DTC 
and compared them with 47 controls matched for age, 
sex, and cardiovascular risk in the case-control study. 
Sixteen patients were diagnosed with rectal cancer, 
10 with colon cancer, 8 with gastric cancer, 8 with pan-
creatic cancer, and 2 with small bowel cancer. Only 3 sub-
jects had stage I (based on the American Joint Committee 
on Cancer staging scheme [13]) disease, 4 had stage II, 
19 had stage III, and 18 had stage IV disease. There 
were 3 patients with grade 1 tumours (G1, low grade), 
15 patients with grade 2 (G2, intermediate grade), and 
26 patients with grade 3 (G3, high grade) according to 
the World Health Organisation grading scheme. The ex-
clusion criteria were: any active infection, renal dysfunc-
tion (creatinine > 2 mg/dl), hypo- and hyperthyroidism, 
previous myocardial infarction, stroke or another acute 
vascular event, venous thromboembolism (VTE), known 
bleeding diathesis, and current anticoagulant therapy 
except for low molecular weight heparin administered 
for the last time 12 h or more prior to sample collection. 
The Jagiellonian University Bioethics Committee 
approved the study protocol. Written consent was ob-
tained from each participant.
Laboratory investigations
Fasting blood was taken from the antecubital vein 
between 7 and 9 a.m. Routine laboratory tests were 
used to determine blood cell count, glucose, creatinine, 
protein, albumin, international normalised ratio (INR), 
activated partial thromboplastin time (APTT), C-reactive 
protein (CRP), and fibrinogen. 
Plasma α2-antiplasmin (α2AP) and plasminogen 
were measured by chromogenic assays (STA Stachrom 
α2-antiplasmin and STA Stachrom plasminogen, Diag-
nostica Stago). Plasma PAI-1 antigen and tPA antigen 
were measured by enzyme-linked immunosorbent 
assays (ELISAs, Hyphen BioMed, Neuville Sur-Oise, 
France). Measurement of TAFI antigen was performed 
with an ELISA (Chromogenix, Lexington, MA, USA). 
Plasma TAFI activity was measured by a chromogenic 
assay using the ACTICHROME® Plasma TAFI Activity Kit 
(American Diagnostica). Soluble thrombomodulin (sTM) 
was measured by an ELISA (Diagnostica Stago, Asniéres, 
France). vWF antigen (vWF:Ag) was measured by latex 
immunoassay on a STAR coagulation instrument (Diag-
nostica Stago, Asnieres, France).
Thrombin-antithrombin complexes (TAT), markers of 
thrombin generation, were determined in citrated plas-
ma using an ELISA (Siemens, Marburg, Germany). Two 
plasma platelet activation markers, i.e. soluble CD40 
ligand (sCD40L) and soluble P-selectin, were assessed 
by ELISA (R&D Systems, Minneapolis, MN, USA).
Blood for clot lysis assay was collected into tubes 
containing 0.109 M trisodium citrate and centrifuged 
within 20 min at 1500 g. Plasma was frozen and stored 
at –80°C until analysis. Technicians blinded to the origin 
of the samples performed all measurements. Intra-as-
say and inter-assay coefficients of variation were < 8%.
Clot lysis assay with and without TAFI 
inhibition
Clot lysis time (CLT) was measured as described 
elsewhere in detail [12]. Briefly, to 75 ml of citrated 
plasma we added TF (Innovin, dilution 105 times), CaCl2 
(final concentration, 17 mmol/l), t-PA (final concentra-
tion, 30 U/ml), and phospholipid vesicles (final concen-
tration, 10 mmol/l). HEPES buffer (25 mmol/l HEPES, 
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137 mmol/l NaCl, 3.5 mmol/l KCl, 3 mmol/l CaCl2, 0.1% 
bovine serum albumin, pH 7.4) was added to make 
a total volume of 150 ml. Phospholipid vesicles con-
sisting of 40% L-a-dioleoylphosphatidylcholine, 20% 
L-a-dioleoylphosphatidylserine, and 40% L-a-dioleoyl-
phosphatidylcholine (all from Sigma Chemical Co., 
St. Louis, MO) were prepared as described by Lisman 
et al. [14]. Total phospholipid content of the vesicles 
was determined by phosphate analysis according to 
Rouser et al. [15].
The solution was thoroughly mixed. Turbidity at 
405 nm of 100 ml of the mixture was measured in time 
at 37°C using a Spectramax 340 kinetic microplate read-
er (Molecular Devices Corp., Menlo Park, CA). The time 
from the midpoint of the clear to maximum turbid tran-
sition (clot formation) to the midpoint of the maximum 
turbid to clear transition (clot lysis) was defined as CLT. 
Contribution of TAFI to CLT was assessed in experiments 
by adding carboxypeptidase inhibitor from potato (CPI, 
Calbiochem, La Jolla, CA, final concentration, 25 mg/ml), 
a specific inhibitor of activated TAFI [15], to the plasma. 
Statistical analysis
Data are expressed as median (interquartile range), 
number (percentage), or mean (standard deviation). 
The Shapiro-Wilk test was used to determine normal 
data distribution. Student t test was used to assess be-
tween-group differences for normally distributed con-
tinuous variables, and the Mann-Whitney U test was 
used for variables of non-normal distribution. The Pear-
son correlation coefficient was used to evaluate sim-
ple linear relationships between variables. Clinical and 
laboratory variables that showed an association with 
CLT in the univariate model (p < 0.2) and did not show 
substantial correlations (r > 0.6) with another indepen-
dent variable were included in the multiple regression 
analysis. The Hosmer-Lemenshow test was used to 
check the goodness of fit of the model. The results were 
presented after adjustment for clusters of confounding 
variables that are markers of different mechanisms: in-
sulin resistance (BMI) and inflammation (fibrinogen and 
CRP). The significance level was set at p < 0.05. 
Results
Patient characteristics 
There were no differences in age, sex, and cardio-
vascular risk factors between the patient and control 
groups [12]. The cancer group had higher CRP, fibrino-
gen, white blood cells (WBC) and platelets, higher INR 
and longer APTT, while albumin and protein were lower 
(Table I). Patients with lower grading (G1 + G2) com-
pared with subjects with G3 tumours had higher BMI 
[12], albumin, and lower fibrinogen (Table I). 
Clot lysis
In the DTC group CLT (by 22.3%) and CLT CPI (by 
27.4%) were longer compared with control subjects 
(Table II), indicating that TAFI inhibition did not abolish 
the intergroup differences in lysis. Patients with higher 
grading G3 compared to those with grading (G1 + G2) 
had longer CLT and CLT CPI (Table II).
Fibrinolysis parameters
DTC patients had higher PAI-1 antigen, TAFI, both 
antigen and activity, compared with the control group 
(Table I). There was a non-significant trend toward low-
er tPA antigen in cancer patients. There were no dif-
ferences between the groups in plasminogen and anti-
plasmin (Table I). Patients with G3 tumours, compared 
with those with lower grading (G1 + G2), had higher 
tPA antigen as well as TAFI activity and antigen (Table I).
Other circulating markers
The DTC group had higher sCD40L (by 438%) and 
P-selectin (by 197%) compared with controls (Table I), 
indicating increased platelet activation. Cancer pa-
tients had also higher thrombin generation in plasma 
as reflected by TAT, combined with enhanced endothe-
lial injury as reflected by higher sTM and vWF antigen 
compared to the control group. High-grade tumour 
patients had higher sTM and vWF compared with the 
lower-grade patient group (Table I).
Associations
The CLT correlated positively with tPA antigen, PAI-1, 
TAT, TAFI antigen and activity, and vWF (Table III) in can-
cer patients.
Multiple regression analysis showed that indepen-
dent predictors of CLT in DTC patients after adjustment 
for potential confounders were TAT, TAFI activity, and 
vWF, while the only independent predictor of CLT CPI 
was plasma TAT concentration (Table IV). 
There were no differences in demographics, clinical 
and laboratory variables, fibrinolysis parameters, plate-
let markers, clot lysis assay depending on the tumour 
type, and clinical stage of the disease (data not shown). 
Discussion
The present study demonstrated a complex regula-
tion of plasma clot lysis in patients with DTC. We found 
that reduced susceptibility to lysis can be observed both 
in the presence and absence of activated TAFI inhibitor 
(CPI), suggesting that TAFI is not the only major con-
tributor to hypofibrinolysis in this disease. The CLT was 
reduced approximately by half by the addition of CPI, 
which confirms downregulation of fibrinolysis by TAFI in 
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Table I. Laboratory investigations in digestive tract cancer (DTC) patients and control subjects – comparison  
of patients with G3 vs. G1 + G2 tumours of various cell differentiations
Variable Controls (n = 47) DTC (n = 44) G1 + G2 (n = 18) G3 (n = 26)
Routine laboratory tests:
Albumin [g/l] 43.3 ±4.4 39.5 ±7.7◊ 44 (41–47) 38 (33–42)*
Protein [g/l] 71.0 ±5.9 67.7 ±8.8◊ 69.5 (68–75) 68 (61–72)
CRP [mg/l] 1.8 ±1.0 22.3 ±32.1◊ 5.5 (3.7–12) 16.5 (1.9–36.4)
INR 0.99 ±0.1 1.04 ±0.1◊ 1 (1–1.1) 1 (1–1.1)
APTT [s] 27.7 ±2.6 30.5 ±3.8◊ 28.35 (27.7–29.5) 31.4 (28.7–32.9)*
Fibrinogen [g/l] 3.3 ±1.0 4.2 ±1.6◊ 3.51 ±0.9 4.7 ±1.75*
WBC [×103/µl] 6.7 ±1.3 8.3 ±3.1◊ 7.6 (5.7–8.7) 8.3 (6.4–11.1)
RBC [×106/µl] 4.6 ±0.4 5.4 ±0.64 4.93 (4.45–5.29) 4.2 (3.79–4.92)*
Haemoglobin [g/dl] 13.8 ±1.2 12.4 ±2.3◊ 12.9 ±2.6 12.0 ±2.04
Haematocrit (%) 41.4 ±3.2 37.6 ±5.9◊ 39.3 ±6.1 36.5 ±5.6
Platelets [×103/µl] 227.4 ±57.7 302.3 ±127.5◊ 333 (211–301) 349.5 (230–386)
Fibrinolysis parameters:
Plasminogen (%) 102.51 ±10.6 103.77 ±9.9 101.39 ±9.95 105.42 ±9.74
α
2
AP (%) 101.47 ±11.36 103.95 ±12.9 100.5 ±12.5 106.35 ±12.85
tPA [ng/ml] 10.03 ±2.18 8.89 ±3.27 6.98 (5.47–9.9) 9.15 (6.8–12.5)*
PAI-1 [ng/ml] 11.96 ±4.02 14.14 ±5.91◊ 11.23 (8.74–15.03) 16.05 (9.17–18.3)
TAFI
ACT
 [µg/ml] 23.37 ±6.1 27.42 ±5.98◊ 24.78 ±5.17 29.24 ±5.9*
TAFI
ATG
 (%) 94.66 ±14.29 105.27 ±13.44◊ 98.3 ±10.9 110.08 ±13.1*
Platelet markers:
sCD40L [ng/ml] 1.03 (0.88–1.21) 4.51 (3.38–4.79)◊ 4.43 ±1.19 4.25 ±0.92
P-selectin [ng/ml] 198 (178–214) 390 (298–467)◊ 375.33 ±89.55 387.58 ±132.34
Other markers:
TAT [µg/l] 4.9 ±1.52 7.29 ±1.42◊ 6.45 (6.2–7.3) 7.35 (6.2–8.9)
sTM [ng/ml] 2.44 ±0.41 2.86 ±1.24◊ 2.27 ±0.55 3.19 ±1.46*
vWF [IU/dl] 114.6 ±20.6 184.5 ±38.4◊ 158.4 ±27.5 202.6 ±34.5*
Values are given as median (interquartile range), number (percentage), or mean ± SD. CRP – C-reactive protein, INR – international normalized ratio, APTT – 





-antiplasmin, TAFI – thrombin activatable fibrinolysis inhibitor, sCD40L – soluble CD40 ligand, TAT – thrombin–antithrombin complexes, 
sTM – soluble thrombomodulin, vWF – von Willebrand factor antigen. ◊p < 0.05 vs. controls. *p < 0.05 vs. (G1 + G2).
Table II. Clot lysis time (CLT) and clot lysis time in the presence of carboxypeptidase potato inhibitor (CLT CPI) – 
comparison of patients with digestive tract cancer (DTC) – G3 vs. G1 + G2 – and controls
Variables Controls (n = 47) DTC (n = 44) G1 + G2 (n = 18) G3 (n = 26)
CLT [min] 83.85 ±13.3 102.6 ±20.1◊ 99.5 ±16.8 109.62 ±19.4*
CLT CPI [min] 42.14 ±6.4 53.7 ±11.5◊ 49.83 ±9.87 56.38 ±12
Data are given as mean ± SD. ◊p < 0.05 vs. controls. *p < 0.05 vs. (G1 + G2).
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our patients. Elevated activity and antigen of TAFI were 
previously described in cancer patients [7–9], includ-
ing DTC, which is consistent with this report. Elevated 
activated TAFI might be explained by higher thrombin 
formation, which increases TAFI activation occurring 
efficiently in complexes with TM, of which a soluble 
form was significantly increased in the DTC patients, 
suggesting that vascular injury/endothelial activation 
in cancer promote TM-mediated pro-and anticoagulant 
effects [16]. A novel finding is that TAFI activity is an 
independent predictor of CLT in the DTC patient group, 
which suggests a role of this inhibitor in the regulation 
of lysis in cancer. Moreover, our study provides evidence 
that patients with high-grade tumours (G3) have longer 
CLT compared with the lower grade cancer group (G1 + 
G2), which supports the concept that dysregulated hae-
mostasis, including efficiency of fibrinolysis measurable 
in plasma of circulating blood, is more pronounced in 
more advanced malignant disease. In addition, elevated 
TAFI levels in the G3 group may lead to a hypothesis 
that in higher-grade tumours TAFI levels have a more 
potent role in fibrinolysis impairment compared to low-
er-grade cancer patients. This concept merits further in 
vitro investigation to elucidate the mechanisms of this 
observation.
Our current findings highlight the role of increased 
thrombin generation also in the degradation of plas-
ma clots in cancer patients, probably in part by the 
formation of denser clots [17]. Previously we showed 
enhanced thrombin generation in DTC patients [12]. 
Associations between clot lysis and thrombin genera-
tion have also been reported in patients with multiple 
myeloma [18] as well in those with other non-malignant 
prothrombotic disorders using different methodologi-
cal approaches [19, 20]. The current study unexpectedly 
demonstrated that thrombin generation, reflected by 
plasma TAT levels, can predict CLT following TAFI inhi-
bition, suggesting a potent impact of thrombin on clot 
structure and/or efficiency of lytic mechanisms in this 
clinical setting. Since thrombin generation has been 
shown to predict thromboembolism in various malig-
nant diseases by Ay et al. [21], our observations might 
support the concept indicating that this harmful effect 
of thrombin could be in part mediated by hypofibrino-
lysis. A larger patient group with long-term follow-up is 
needed to assess the links among thrombin, TAFI, fibri-
nolysis, and clinically overt thromboembolic manifesta-
tions in cancer patients.
Interestingly, we showed that the plasma vWF level 
correlates with CLT and is an independent predictor of 
CLT in DTC patients. This novel finding suggests that vWF 
is actively involved in clot fibrinolysis in cancer patients. 
Two major functions of vWF, the largest human plasma 
protein, are its involvement in platelet adhesion and car-
riership of factor VIII in circulation. Several studies have 
demonstrated increased plasma vWF antigen levels in 
malignancies, including CRC [22], which is in line with 
our findings. It is unclear whether there are associations 
between vWF level, fibrinolysis, and cancer growth. 
Damin et al. [23] reported associations between plas-
ma vWF levels  and tumour staging, invasion of adja-
cent organs by the tumour, and the presence of distant 
metastases in CRC. We found that patients with G3 tu-
mours (n = 26), compared to those with lower grading 
Table III. Correlations of clot lysis time (CLT) and haemostatic parameters in cancer patients
tPA PAI-1 TAT TAFIACT TAFIATG Antiplasmin vWF
CLT r = 0.49 r = 0.49 r = 0.72 r = 0.82 r = 0.55 r = 0.53 r = 0.6
p = 0.001 p = 0.001 p < 0.001 p < 0.001 p < 0.001 p < 0.001 p < 0.001
Abbreviations see Table I.
Table IV. Independent predictors of clot lysis time (CLT) and clot lysis time in the presence of carboxypeptidase 
potato inhibitor (CLT CPI) in the cancer patients group – multiple stepwise regression analysis models after 
adjustment for potential confounders
Independent predictors of CLT Independent predictors of CLT CPI
TAT TAFI activity vWF antigen TAT
R2 = 0.84 R2 = 0.58
Slope estimate = 0.28 Slope estimate = 0.49 Slope estimate = 0.25 Slope estimate = 0.67 
SE = 1.35 SE = 0.36 SE = 0.05 SE = 0.88
p = 0.006 p < 0.001 p = 0.01 p < 0.001
Abbreviations see Table I.
109Determinants of hypofibrinolysis in patients with digestive tract cancer
Gastroenterology Review 2016; 11 (2)
(n = 18), had higher plasma vWF antigen levels. Howev-
er, we failed to show such correlations, which might be 
because of the cancer type heterogeneity in the present 
DTC group. Interestingly, we found that CLT is positively 
associated with vWF antigen, which might suggest that 
this protein alters the efficiency of plasmin-mediated ly-
sis, probably in part by affecting fibrin clot structure. This 
novel association and the potential role of vWF in modu-
lation of thrombus properties merit further investigation 
given the multiple prothrombotic non-cancer disorders in 
which vWF levels rise substantially
We have also hypothesised that enhanced platelet 
activation in DTC patients might be involved in hypofi-
brinolysis. The rationale for this concept is derived from 
reports showing that platelet activation, which leads 
to the release of a number of substances, including 
proteins from α granules (e.g. platelet factor 4 (PF4), 
factor V, vWF, fibrinogen, angiogenin, vascular endothe-
lial growth factor) and dense granules (predominantly 
various polyphosphate) unfavourably alters clot charac-
teristics [24]. Elevated platelet counts in subjects with 
chronic inflammatory diseases have been reported to 
be associated with unfavourably altered clot properties, 
including a positive correlation with CLT [25]. We found 
that plasma platelet markers levels, P-selectin and 
sCD40L, are elevated in the cancer group, which is con-
sistent with previous findings [26, 27]. The present study 
showed no association between CLT and these platelet 
markers, indicating a minor, if any, role of P-selectin and 
sCD40L in clot structure and function in cancer patients. 
Our study has several limitations. There were 
a small number of patients enrolled in the study. How-
ever, our study was sufficiently powered to show inter-
group differences, although the subgroup analysis, es-
pecially regarding subjects with various grades, should 
be interpreted with caution. Variables were determined 
at a single point in time. It would be of interest to as-
sess post-treatment fibrin clot analysis and repeat the 
measurements after follow-up; however, treatment-as-
sociated alteration of CLT and the potential association 
with clinical outcome were beyond the scope of the cur-
rent study. Fibrinolysis in cancer patients could also be 
modified by several environmental factors not specifi-
cally addressed by the present study, for instance active 
or passive tobacco smoking [28]. Finally, the associa-
tions reported in the study do not necessarily indicate 
cause-effect relationships. 
Conclusions
We showed that TAFI, thrombin generation, and vWF, 
commonly elevated in cancer patients, are involved in 
hypofibrinolysis assessed using a global plasma-based 
assay in the DTC group. Our findings, by showing novel 
potential determinants of slower fibrin degradation in 
cancer patients, provide new insights into the disturbed 
balance between blood coagulation and fibrinolysis 
in cancer patients, which is highlighted by more pro-
nounced impairment of clot lysis in subjects with more 
advanced cancer. It remains to be established whether 
these alterations might represent an important throm-
boembolic risk factor in these types of malignancy.
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